This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Meningococcal vaccination schedule

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

 

Age

Primary/booster

Dose

Two months

Primary*

One dose - 4CMenB vaccine

Four months

Primary*

One dose - 4CMenB vaccine

12-13 months

Primary (Men C) and Booster (Hib)

Booster (4CMenB)

One dose - Hib/MenC conjugate vaccine

One dose - 4CMenB vaccine

Around 14 years

Booster

One dose - MenACWY conjugate vaccine

* Although the summary of product characteristics for 4CMenB states that three doses should be given in those less than one year of age, the Joint Committee on Vaccination and Immunisation have advised that the provision of two doses of 4CMenB in infancy at two and four months of age with a booster dose at 12-13 months of age would likely be sufficient to provide substantial protection against MenB IMD in infants and toddlers

Check uptodate details in the The Green Book before prescribing/administering a vaccine.

Check the Summary of Product Characteristics (SPC) of the influenza vaccination before prescribing/administering a vaccine.

Reference:

  • Immunisation Against Infectious Disease - "The Green Book".Chapter 22 Meningococcal (April 2019).

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.